Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.04 USD
-0.09 (-0.59%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $15.00 -0.04 (-0.27%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ASMB 15.04 -0.09(-0.59%)
Will ASMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Shares Rise on Broad Support for Opioids Settlement
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Other News for ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences doses first participant in Phase 1b trial of ABI-4334
Assembly Biosciences closes $12.6M in equity financings